Hansoh Pharma's Class 1 Oral New Drug HS-10501 Granted IND Approval for Type 2 Diabetes and Obesity
Hansoh Pharma
Pharmaceutical Research, Production, and Sales
The official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) announced,Hansoh Pharma's Class 1 new drug HS-10501 tablets approved for clinical trialsProposed Development TreatmentAdult Type 2 Diabetes and Adult Obesity. According to the announcement by Hansoh Pharma, this is the company'sA small-molecule new drug developed in-house。
Source: CDE official website
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder, primarily characterized by insulin resistance, which prevents insulin from functioning effectively. For these patients, the use of insulin alone does not adequately improve their condition, necessitating other types of hypoglycemic agents to control blood glucose levels.
Operation | Valley
Has the ADC illusion shattered? Another blockbuster drug fails to meet the challenge
Merck Just Made a Move, and Wantai BioTech Was Greatly Affected?
New Development | U.S. Requires All CAR-T Therapies to Add Black Box Warnings
Scan to add me: Join the group for communication, informed exposure, and reprint authorization.
If there are any issues with the content, please contact us by email:
jianshiju@boyamedia.com
For business cooperation, please contact: 13288688512